University of Kansas Medical Center (KUMC)
University of Kansas Medical Center (KUMC)
Kansas City, Kansas, United States10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 2 | 2026-09-29 | NCT06995677 | |
| NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Muscular Disorders, Atrophic, X-linked disease, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Active, not recruiting | Phase 2 | 2026-09-15 | NCT05996003 | |
| Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB) | Complex Cardiovascular Surgery With Cardiopulmonary Bypass | Recruiting | Phase 3 | 2026-08-18 | NCT07094087 | |
| PROACTIVE-HF IDE Trial Heart Failure NYHA Class III | cardiovascular disorder, heart disorder, heart failure | Active, not recruiting | Not applicable | 2026-07-24 | NCT04089059 | |
| Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9 | autosomal recessive limb-girdle muscular dystrophy type 2I | Active, not recruiting | Phase 3 | 2026-07-02 | NCT07678775 | |
| PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III | cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-06-29 | NCT05934487 | |
| An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Enrolling by invitation | Phase 3 | 2026-04-17 | NCT05667493 | |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) | familial chylomicronemia syndrome, familial lipoprotein lipase deficiency | Active, not recruiting | Phase 3 | 2025-12-12 | NCT05130450 | |
| Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure | cardiovascular disorder, congestive heart failure, heart disorder, heart failure | Active, not recruiting | Phase 2 | 2025-12-03 | NCT05598333 | |
| CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Active, not recruiting | Phase 3 | 2025-12-01 | NCT05681351 |